Acknowledgements

This document has been prepared by the Global Tuberculosis Programme of the World Health Organization (WHO) with support from professionals from a range of specialties who have extensive expertise and experience in public health policy, tuberculosis (TB) programme management, and the care and management of patients with TB. This 2023 edition updates and replaces the first edition, which was released in 2016.
This 2023 edition was developed through in-person and virtual meetings of the Scientific Target Regimen Profiles (TRP) Development Group (STG) and other stakeholders, and input received via public comment.
The World Health Organization (WHO) acknowledges and is grateful for the time and support of all individuals who have contributed to these efforts.
The production and writing of this document – Target regimen profiles for tuberculosis treatment – was coordinated by Fuad Mirzayev, with the support of Samuel Schumacher and Medea Gegia under the guidance of Matteo Zignol and the overall direction of Tereza Kasaeva, Director of the WHO Global Tuberculosis Programme.
The main parts of the document were written and compiled by the core writing group consisting of Christian Lienhardt, Samuel Schumacher and Fuad Mirzayev. Particularly valuable contributions were made by the TRP group leads: Gerry Davies, Kelly Dooley, Payam Nahid and Charles Wells.
Modelling work included in the sections on cost considerations and trade-offs was performed by Tess Ryckman and Emily Kendall, who also drafted the respective sections. The stakeholder survey was led by Marie Leudière and Christian Lienhardt. Sections on cross-cutting aspects were drafted by STG members and two other individuals (drug susceptibility testing: Daniela Cirillo, Ramya Gopinath and Eugenia Di Meco; post-TB lung disease: Gavin Churchyard, Carole Mitnick, Andrea Rachow and Robert Wallis; and equitable access and transparent pricing: Grania Brigden and Cherise Scott).
The meeting, modelling work and document were funded through a grant provided by USAID.